Aegis Capital Corp Reiterates Buy Rating of NeoStem, Inc.

Business & Professional Services

Share Tweet

Aegis Capital Corp Reiterates Buy Rating of NeoStem, Inc.

New York, NY / June 4, 2014 / Market Exclusive announces that Aegis Capital Corp has reiterated a Buy rating and 12-month price target of $21.00 on NeoStem, Inc. (NASDAQ:NBS).

According to the Aegis report “In the wake of Neostem's acquisition of the privately-held firm California Stem Cell, Inc. (CSC), which established Neostem's platform in cancer immunotherapy, five-year survival data with CSC's lead drug candidate, melapuldencel-T, were showcased in a poster presentation at the American Society for Clinical Oncology (ASCO).”

NeoStem is a leader in the emerging cellular therapy industry, pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. The business includes the development of novel proprietary cell therapy products as well as a revenue-generating contract development and manufacturing service business. This combination has created an organization with unique capabilities for cost effective in-house product development and immediate revenue and cash flow generation.

About Market Exclusive

Market Exclusive Is a financial portal geared to engaging discussion on current financial topics. Market Exclusive is not an investment advisor.

The owner of this announcement warrants that:(i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: marketexclusive